Recordati

Update in progress

REC.MI (Milan)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Recordati Industria Chimica e Farmaceutica S.p.A., with its subsidiaries, develops, produces and markets medicines in Italy, the US, Europe, Russia, Turkey, North Africa and worldwide. It operates through Specialty/Primary Care and Rare Diseases. Notable products include REC 0545, Isturia, Cystadrops, Carbaglu, Qarziba, Fortivda, Sylvant, ENJAYMO, Urorec, Avodart, Livazo, Eligard and pasireotide (Phase II). Founded 1926, headquartered in Milan.

Company score

Sentiment: 0.10; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.08; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive